PURPOSE: To update the incidence of late toxicity of RTOG 9406, a three-dimensional conformal radiation therapy (3DCRT) dose escalation trial for prostate cancer. METHODS AND MATERIALS: A total of 1,084 men were registered to this Phase I/II trial of 3DCRT (eligible patients, 1,055). The dose for level I was 68.4 Gy; 73.8 Gy for level II; 79.2 Gy for level III; 74 Gy for level IV; and 78 Gy for level V. Patients in levels I to III received 1.8 Gy/fraction, and those in levels IV to V received 2.0 Gy/fraction. Disease group I patients were treated at the prostate only, group 2 patients were treated at the prostate and at the seminal vesicles with a prostate boost, and group 3 patients were treated at the prostate and seminal vesicles. The median follow-up period for surviving patients was 6.1 y (level V) to 12.1 y (level I). RESULTS: The incidence rates of RTOG grade 3 or less gastrointestinal or genitourinary toxicity were 3%, 4%, 6%, 7%, and 9% in group 1 and 6%, 2%, 6%, 9%, and 12% in group 2 at dose levels of I, II, III, IV, and V, respectively. In group 1, level V patients had a higher probability of grade 2 late or greater gastrointestinal or genitourinary toxicity than those in levels I, II, and III (hazard ratio [HR] = 1.93, p = 0.0101; HR = 2.29, p = 0.0007; HR = 2.52, p = 0.0002, respectively). In group 2, dose level V patients had a higher probability of grade 2 or greater late gastrointestinal or genitourinary toxicity than those in dose levels II, III, and IV (HR = 2.61, p = 0.0002; HR = 2.22, p = 0.0051; HR = 1.60, p = 0.0276, respectively). CONCLUSIONS: Tolerance to high-dose 3DCRT remains excellent. There is significantly more grade 2 or greater toxicity with a dose of 78 Gy at 2 Gy/fraction than with 68.4 Gy to 79.2 Gy at 1.8 Gy/fraction and with 74 Gy at 2 Gy/fraction.
PURPOSE: To update the incidence of late toxicity of RTOG 9406, a three-dimensional conformal radiation therapy (3DCRT) dose escalation trial for prostate cancer. METHODS AND MATERIALS: A total of 1,084 men were registered to this Phase I/II trial of 3DCRT (eligible patients, 1,055). The dose for level I was 68.4 Gy; 73.8 Gy for level II; 79.2 Gy for level III; 74 Gy for level IV; and 78 Gy for level V. Patients in levels I to III received 1.8 Gy/fraction, and those in levels IV to V received 2.0 Gy/fraction. Disease group I patients were treated at the prostate only, group 2 patients were treated at the prostate and at the seminal vesicles with a prostate boost, and group 3 patients were treated at the prostate and seminal vesicles. The median follow-up period for surviving patients was 6.1 y (level V) to 12.1 y (level I). RESULTS: The incidence rates of RTOG grade 3 or less gastrointestinal or genitourinary toxicity were 3%, 4%, 6%, 7%, and 9% in group 1 and 6%, 2%, 6%, 9%, and 12% in group 2 at dose levels of I, II, III, IV, and V, respectively. In group 1, level V patients had a higher probability of grade 2 late or greater gastrointestinal or genitourinary toxicity than those in levels I, II, and III (hazard ratio [HR] = 1.93, p = 0.0101; HR = 2.29, p = 0.0007; HR = 2.52, p = 0.0002, respectively). In group 2, dose level V patients had a higher probability of grade 2 or greater late gastrointestinal or genitourinary toxicity than those in dose levels II, III, and IV (HR = 2.61, p = 0.0002; HR = 2.22, p = 0.0051; HR = 1.60, p = 0.0276, respectively). CONCLUSIONS: Tolerance to high-dose 3DCRT remains excellent. There is significantly more grade 2 or greater toxicity with a dose of 78 Gy at 2 Gy/fraction than with 68.4 Gy to 79.2 Gy at 1.8 Gy/fraction and with 74 Gy at 2 Gy/fraction.
Authors: Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2007-08-31 Impact factor: 7.038
Authors: Janice K Ryu; Kathryn Winter; Jeff M Michalski; James A Purdy; Arnold M Markoe; John D Earle; Carlos A Perez; Mack Roach; Howard M Sandler; Alan Pollack; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-15 Impact factor: 7.038
Authors: Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: J M Michalski; J A Purdy; K Winter; M Roach; S Vijayakumar; H M Sandler; A M Markoe; M A Ritter; K J Russell; S Sailer; W B Harms; C A Perez; R B Wilder; G E Hanks; J D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: Berit L Madsen; R Alex Hsi; Huong T Pham; Jack F Fowler; Laura Esagui; John Corman Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-15 Impact factor: 7.038
Authors: Patrick A Kupelian; Twyla R Willoughby; Chandana A Reddy; Eric A Klein; Arul Mahadevan Journal: Int J Radiat Oncol Biol Phys Date: 2007-06-04 Impact factor: 7.038
Authors: David P Dearnaley; Matthew R Sydes; John D Graham; Edwin G Aird; David Bottomley; Richard A Cowan; Robert A Huddart; Chakiath C Jose; John Hl Matthews; Jeremy Millar; A Rollo Moore; Rachel C Morgan; J Martin Russell; Christopher D Scrase; Richard J Stephens; Isabel Syndikus; Mahesh K B Parmar Journal: Lancet Oncol Date: 2007-06 Impact factor: 41.316
Authors: Susan L Tucker; Lei Dong; Walter R Bosch; Jeff Michalski; Kathryn Winter; Radhe Mohan; James A Purdy; Deborah Kuban; Andrew K Lee; M Rex Cheung; Howard D Thames; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-02 Impact factor: 7.038
Authors: Jeff M Michalski; Hiram Gay; Andrew Jackson; Susan L Tucker; Joseph O Deasy Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Johnny Kao; Amanda Zucker; Jonathan Timmins; Shankar Taramangalam; Jeffrey Pettit; Aaron J Woodall; Edward Loizides; Andrew T Wong Journal: Mol Clin Oncol Date: 2017-06-08
Authors: Awad A Ahmed; Brian Egleston; Pino Alcantara; Linna Li; Alan Pollack; Eric M Horwitz; Mark K Buyyounouski Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-09 Impact factor: 7.038